FDA Offers Insights On Second Interchangeable Adalimumab
Agency Sheds Light On Decision To Deem A Second Humira Biosimilar Interchangeable
The FDA recently approved a second US Humira biosimilar, from Pfizer, as interchangeable – just a few months after the launch of Boehringer Ingelheim’s interchangeable Cyltezo – despite first interchangeable biosimilars benefiting from a year of exclusivity. Now, the agency has shed further light on the decision in response to Generics Bulletin queries.
